Headquartered in Denmark and operating in around 80 countries, Novo Nordisk employs approximately 67,900 people and markets products in roughly 170 countries
For readers comparing brands, review pages that detail licensing, testing labs, payment partners, and historical uptime can help separate hype from substance
April 2026 Category 2 Update On April 15, 2026, the FDA confirmed removal of injectable GHK-Cu from Category 2 because the original nominations were withdrawn
36 Within three weeks of starting the spray, she developed gingival pigmentation and a rapidly growing anterior maxillary lesion that was ultimately diagnosed as pT4 melanoma with alveolar bone invasion
In the SURPASS program, gastrointestinal side effects associated with the use of tirzepatide were similar to those observed with semaglutide and GLP1-RA drugs in general, both in terms of frequency and duration [3]
Therapeutic tumor-specific cell cycle block induced by methionine starvation in vivo
